ABT-102

• UNSPSC Description:

  ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain[1][2].

• Target Antigen:

  TRP Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/abt-102.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=CC=CC2=C1C=NN2)N[C@@H]3CCC4=C3C=CC(C(C)(C)C)=C4

• Molecular Weight:

  348.44

• References & Citations:

  [1]Lukin K, et al. Development of a Large Scale Asymmetric Synthesis of Vanilloid Receptor (TRPV1) Antagonist ABT-102. Organic Process Research & Development, 2007, 11(3):578-584.|[2]Rowbotham MC, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011 May;152(5):1192-1200.

• Shipping Conditions:

  Room temperature

• Storage Conditions:

  Store at room temperature 3 years

• Clinical Information:

  Phase 1

• CAS Number:

  808756-71-0